Breaking Update: Here’s a clear explanation of the latest developments related to Breaking News:KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India– What Just Happened and why it matters right now.
KIMS Hospitals has become the first centre in India to introduce Adaptive Deep Brain Stimulation (aDBS), marking a major advancement in neurotechnology for patients with Parkinson’s disease.
This sensing-enabled, closed-loop system builds on the previously developed Percept Platform and now integrates BrainSense technology. As a result, the system enables real-time brain-sensing capabilities and delivers a more personalised neuromodulation therapy experience.
From Conventional DBS to Adaptive Closed-Loop Technology
Traditionally, Deep Brain Stimulation (DBS) has helped reduce tremors, rigidity, and slowness of movement in people living with Parkinson’s disease. Earlier DBS devices delivered constant levels of stimulation, regardless of symptom fluctuations.
However, adaptive DBS represents a significant evolution. Unlike earlier versions, this system continuously monitors brain activity—specifically local field potentials in the beta frequency range—and adjusts stimulation levels in real time.
Consequently, the device automatically increases or decreases stimulation in response to fluctuations in brain signals. This dynamic feedback loop reduces the need for patients or physicians to manually modify settings. Nevertheless, specialist doctors still define and control the stimulation thresholds and parameters to ensure safe and effective therapy.
Clinical Advantages of Adaptive DBS
Dr. Guruprasad Hosurkar, Director & Lead Consultant in Neurology and Head of the Parkinson’s Disease and Movement Disorder Programme at KIMS Hospitals, highlighted several major benefits of adaptive DBS.
First, the system significantly reduces the need for patients to manually adjust device settings because it responds automatically to symptom changes.
Second, studies indicate that overall stimulation usage may decrease by nearly 50%. Therefore, patients could experience extended battery life and potentially lower long-term replacement costs.
Third, because the device limits unnecessary excess stimulation over prolonged periods, it may reduce the risk of stimulation-related side effects in surrounding brain tissue.
Regulatory Approval and Global Rollout
Adaptive DBS first received regulatory approval in the United States and was later introduced in select international centres, including Japan. Earlier this year, India granted approval for the technology. Subsequently, KIMS Hospitals, Bengaluru, emerged as one of the first hospitals in the country to implement it.
Implementation Plan and Role of AI
As per the press release, Dr. Raghuram Gopalakrishnan, Director & Senior Consultant and Head of Stereotactic and Functional Neurosurgery, outlined the hospital’s rollout strategy.
Initially, the team will upgrade select existing DBS patients to the adaptive platform through a software update and advanced programming interface. In the first phase, the hospital plans to transition four to five eligible patients in early March.
Furthermore, he emphasised that artificial intelligence plays a crucial role in the system. The embedded AI algorithm analyses neuronal waveforms and adjusts stimulation parameters accordingly. Thus, adaptive DBS demonstrates how AI-driven tools can enhance precision and improve patient outcomes when used responsibly in medicine.
Advancing Personalised Neurological Care
Dr. Nitish Shetty, Managing Director of KIMS Hospitals (Krishna Institute of Medical Sciences), Bengaluru, described the launch as a transformative milestone. He stated that introducing adaptive closed-loop DBS strengthens the hospital’s commitment to delivering personalised neurological care aligned with global standards.
By adopting this cutting-edge, evidence-based technology, KIMS Hospitals reinforces its dedication to innovation and improved quality of life for patients with Parkinson’s disease. Ultimately, adaptive DBS moves Indian neurological care closer to fully individualised therapy—where treatment responds in real time to the brain’s own signals.